Sony Biotechnology is closely monitoring the COVID-19 situation across the globe. Our first priority is to ensure the health and safety of our employees in affected areas around the world. We are reviewing guidance from the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), government agencies, and health officials in a variety of affected countries.

  Dr. Chris Emig, Founder and Chief Executive of Augmenta Bioworks The B-cell receptor repertoire can now be queried by next generation sequencing (NGS) at a scale that enables the rapid collection of millions of antibody sequences from any given individual. The resulting pool of rationally selected antibodies gives researchers access to a comprehensive database of antigen-specific binders and increases the chances of identifying the best antibody sequences. The growing volume of such NGS antibody repositories opens opportunities for alternative methods of therapeutic antibody discovery. Augmenta Bioworks, a biotechnology company headed by Chris Emig, PhD, Co-Founder and Chief Executive Officer, is actively engaged in the discovery of new therapeutics by harnessing the most powerful force in the fight against disease—natural human immunity. This group has developed a novel strategy called the DeepGrid™ platform, which combines single-cell sorting with RNA sequencing to pinpoint the protective immune response of individuals and translate these discoveries into therapies. Dr. Emig explains, "We’re currently working on immune profiling and antibody discovery. Augmenta provides deep insights into human immune repertoires and a technical suite for discovering antibodies of high therapeutic potential. We work with a range of scientists, from academics seeking better insights into human immunity...

Learn how cell sorting can be integrated into workflows for multiomic analysis of double emulsion microdroplets.

Learn about the approaches used by two scientific groups who have accelerated antibody discovery with these pipeline technologies.

Join our panel discussion on how research labs are adapting to support COVID-19 research and learn about flow cytometry approaches used for studying COVID-19 immunopathology.

In this webinar you will learn about the latest approaches in single nucleus transcriptomics and ATAC-Seq, and how they can be used on flash-frozen primary human and mouse tissues to decipher tissue-specific epigenetic regulation.

In this educational article we compare spectral technology to traditional flow cytometry and the advantages offered by spectral flow cytometry.

In this webinar, we will explore the key considerations when designing multicolor panels for use on the ID7000™ spectral cell analyzer.

Join this educational webinar to learn about the key aspects of sorting that should be considered to ensure optimal cell sorting results for different applications.

Getting the most from your cell sorter Fluorescence-activated cell sorting (FACS) is an increasingly common step in many life science research applications, from sequencing to protein design to immunotherapy. No matter which downstream application is used, it is possible to take steps to optimize the purity, efficiency, and reliability of each sort performed.